 |
14 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- | Tredaptive (niacin controlled release/laropiprant) / Merck (MSD), laropiprant/niacin/simvastatin (MK-524B) / Merck (MSD)
Enrollment change: A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) (clinicaltrials.gov) - May 28, 2012
P3, N=977, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=1268 --> 977
- | Tredaptive (niacin controlled release/laropiprant) / Merck (MSD), laropiprant/niacin/simvastatin (MK-524B) / Merck (MSD)
Trial termination: Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (clinicaltrials.gov) - Apr 25, 2012
P3, N=1139, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=1268 --> 977 Completed --> Terminated; Business Reasons
- | Tredaptive (niacin controlled release/laropiprant) / Merck (MSD), laropiprant/niacin/simvastatin (MK-524B) / Merck (MSD)
Trial termination: A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) (clinicaltrials.gov) - Apr 11, 2012
P3, N=977, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; Business Reasons Active, not recruiting --> Terminated